. Subcutaneous IGF-1 is not beneficial in 2-year ALS trial. Neurology. 2008 Nov 25;71(22):1770-5. PubMed.


Please login to recommend the paper.


  1. It would be appropriate to try doing a trial of IGF-1 BP3
    (Iplex) at a
    higher dose. As ALS patients, many of us do not have two years
    to waste on
    stupidity. I used Iplex briefly before the lawsuit rendered it
    unavailable. My "anecdotal" evidence supported slight improvement
    in a short period of
    time. Worth a shot when it comes to people waiting to die,
    isn't it?

    View all comments by Deborah Gattoni

Make a Comment

To make a comment you must login or register.